S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
S&P 500   5,250.85 (+0.04%)
DOW   39,767.80 (+0.02%)
QQQ   444.42 (-0.09%)
AAPL   170.98 (-1.34%)
MSFT   420.41 (-0.24%)
META   486.27 (-1.54%)
GOOGL   150.50 (-0.25%)
AMZN   180.28 (+0.25%)
TSLA   176.57 (-1.81%)
NVDA   906.00 (+0.39%)
NIO   4.61 (-1.28%)
AMD   181.21 (+0.90%)
BABA   72.49 (+1.26%)
T   17.61 (+0.34%)
F   13.25 (+1.45%)
MU   118.18 (-0.81%)
CGC   9.70 (+1.57%)
GE   175.26 (-2.70%)
DIS   122.67 (+1.40%)
AMC   3.70 (-14.75%)
PFE   27.88 (+0.36%)
PYPL   67.20 (+0.95%)
XOM   115.76 (+0.69%)
NASDAQ:BCDA

BioCardia (BCDA) Stock Price, News & Analysis

$0.41
-0.01 (-1.81%)
(As of 12:14 PM ET)
Today's Range
$0.39
$0.41
50-Day Range
$0.38
$0.58
52-Week Range
$0.36
$2.92
Volume
218,091 shs
Average Volume
392,461 shs
Market Capitalization
$10.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

BioCardia MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
899.8% Upside
$4.00 Price Target
Short Interest
Bearish
6.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.23mentions of BioCardia in the last 14 days
Based on 7 Articles This Week
Insider Trading
Balanced
Insiders Both Buying and Selling
Proj. Earnings Growth
Decreasing
From ($0.52) to ($0.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.53 out of 5 stars

Medical Sector

716th out of 939 stocks

Biological Products, Except Diagnostic Industry

121st out of 155 stocks

BCDA stock logo

About BioCardia Stock (NASDAQ:BCDA)

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

BCDA Stock Price History

BCDA Stock News Headlines

BioCardia, Inc. (NASDAQ:BCDA) Short Interest Up 927.5% in March
BioCardia: Q4 Earnings Insights
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
BioCardia (BCDA) Scheduled to Post Earnings on Wednesday
BioCardia Inc.
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
BCDA Mar 2024 1.500 call
BCDA Aug 2024 0.500 call
BCDA Mar 2024 0.500 call
Positive Signs As Multiple Insiders Buy BioCardia Stock
See More Headlines
Receive BCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCardia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:BCDA
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+854.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-11,910,000.00
Net Margins
-2,197.72%
Pretax Margin
-2,197.72%

Debt

Sales & Book Value

Annual Sales
$570,000.00
Book Value
$0.24 per share

Miscellaneous

Free Float
19,721,000
Market Cap
$10.86 million
Optionable
Optionable
Beta
1.50
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

BCDA Stock Analysis - Frequently Asked Questions

Should I buy or sell BioCardia stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioCardia in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BCDA shares.
View BCDA analyst ratings
or view top-rated stocks.

What is BioCardia's stock price target for 2024?

2 Wall Street research analysts have issued 1-year target prices for BioCardia's shares. Their BCDA share price targets range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 899.8% from the stock's current price.
View analysts price targets for BCDA
or view top-rated stocks among Wall Street analysts.

How have BCDA shares performed in 2024?

BioCardia's stock was trading at $0.6642 at the start of the year. Since then, BCDA shares have decreased by 39.8% and is now trading at $0.4001.
View the best growth stocks for 2024 here
.

Are investors shorting BioCardia?

BioCardia saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 1,010,000 shares, an increase of 927.5% from the February 29th total of 98,300 shares. Based on an average daily trading volume, of 378,600 shares, the days-to-cover ratio is presently 2.7 days. Approximately 6.2% of the company's shares are short sold.
View BioCardia's Short Interest
.

When is BioCardia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our BCDA earnings forecast
.

How were BioCardia's earnings last quarter?

BioCardia, Inc. (NASDAQ:BCDA) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.05. The business earned $0.82 million during the quarter, compared to analysts' expectations of $0.04 million. BioCardia had a negative net margin of 2,197.72% and a negative trailing twelve-month return on equity of 645.14%. During the same period in the prior year, the company posted ($0.30) earnings per share.

When did BioCardia's stock split?

BioCardia shares reverse split on the morning of Friday, November 3rd 2017. The 1-12 reverse split was announced on Thursday, November 2nd 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 2nd 2017. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of BioCardia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCardia investors own include Arotech (ARTX), CytoDyn (CYDY), China Gold International Resources (CGG), BioSolar (BSRC), Blink Charging (BLNK), Aurcana Silver (AUNFF), RecycLiCo Battery Materials (AMY) and

When did BioCardia IPO?

BioCardia (BCDA) raised $51 million in an initial public offering on the week of July 20th 2015. The company issued 3,900,000 shares at $12.00-$14.00 per share. Cantor Fitzgerald & Co. served as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers.

Who are BioCardia's major shareholders?

BioCardia's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.16%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Mcclung, Peter Altman and Phillip Md Et Al Frost.
View institutional ownership trends
.

How do I buy shares of BioCardia?

Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCDA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners